Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 46, 2016, Pages E7240-E7249

  Wang, Shu ^a   Campos, Jose ^a   Gallotta, Marilena ^a   Gong, Mei ^a   Crain, Chad ^a   Naik, Edwina ^a   Coffman, Robert L ^a   Guiducci, Cristiana ^a  

^a Dynavax Technologies Corporation   (United States)

Author keywords

Multifunctional CD8+ T cells; PD 1 blockade; TLR9 agonist

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BLOCKING ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 7 RECEPTOR; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; SD 101; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BREAST ADENOCARCINOMA; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; IMMUNOMODULATION; LEUKOCYTE MIGRATION; LONG TERM SURVIVAL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR REJECTION; TUMOR VOLUME; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; NEOPLASM; TUMOR CELL LINE;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; INJECTIONS, INTRALESIONAL; INTERFERON TYPE I; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; TOLL-LIKE RECEPTOR 9; TUMOR MICROENVIRONMENT;

EID: 84995640008     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608555113     Document Type: Article

References (50)

1. Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13(3): 143-158.
2. Herbst RS, et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563-567.
3. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571.
4. Marabelle A, Kohrt H, Caux C, Levy R (2014) Intratumoral immunization: A new paradigm for cancer therapy. Clin Cancer Res 20(7):1747-1756.
5. Brody JD, et al. (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J Clin Oncol 28(28):4324-4332.
6. Kim YH, et al. (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: A phase 1/2 study. Blood 119(2):355-363.
7. Legler DF, et al. (1998) B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 187(4):655-660.
8. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G (2015) Type I interferons in anticancer immunity. Nat Rev Immunol 15(7):405-414.
9. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302-305.
10. Henry RA, Kendall PL (2010) CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. J Immunol 185(3):1460-1465.
11. Rusinova I, et al. (2013) Interferome v2.0: An updated database of annotated interferon- regulated genes. Nucleic Acids Res 41(Database issue):D1040-D1046.
12. Shinall SM, Gonzalez-Fernandez M, Noelle RJ, Waldschmidt TJ (2000) Identification of murine germinal center B cell subsets defined by the expression of surface isotypes and differentiation antigens. J Immunol 164(11):5729-5738.
13. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77(8):4911-4927.
14. Wei F, et al. (2013) Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA 110(27):E2480-E2489.
15. Ahlers JD, Belyakov IM (2010) Memories that last forever: Strategies for optimizing vaccine T-cell memory. Blood 115(9):1678-1689.
16. Halin C, et al. (2005) The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood 106(4):1314-1322.
17. + T cells directly within the tumor microenvironment. J Immunother Cancer 2:3.
18. Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139-2145.
19. Angell H, Galon J (2013) From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25(2):261-267.
20. Vermi W, et al. (2011) Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Invest Dermatol 131(2):426-434.
21. Bald T, et al. (2014) Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 4(6):674-687.
22. Germain C, et al. (2014) Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 189(7):832-844.
23. Bedognetti D, Wang E, Marincola FM (2014) Meta-analysis and metagenes: CXCL-13- driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome. OncoImmunology 3:e28727.
24. Bindea G, et al. (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782-795.
25. Germain C, Gnjatic S, Dieu-Nosjean MC (2015) Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol 6:67.
26. Weiss GR, et al. (2011) Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 17(23):7440-7450.
27. Ji RR, et al. (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61(7):1019-1031.
28. Alistar A, et al. (2014) Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med 6(10):80.
29. Jones GW, Jones SA (2016) Ectopic lymphoid follicles: Inducible centres for generating antigen-specific immune responses within tissues. Immunology 147(2):141-151.
30. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH (2014) Tertiary lymphoid structures in cancer and beyond. Trends Immunol 35(11):571-580.
31. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH (2004) RNA-transfected CD40- activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103(6):2046-2054.
32. Yuseff MI, Pierobon P, Reversat A, Lennon-Duménil AM (2013) How B cells capture, process and present antigens: A crucial role for cell polarity. Nat Rev Immunol 13(7):475-486.
33. Ahmadi T, Flies A, Efebera Y, Sherr DH (2008) CD40 ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 124(1):129-140.
34. + T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184(7):4006-4016.
35. Homann D, et al. (1998) Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: Failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J Virol 72(11): 9208-9216.
36. + dendritic cells. J Exp Med 208(10):2005-2016.
37. Diamond MS, et al. (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208(10):1989-2003.
38. Swann JB, et al. (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 178(12):7540-7549.
39. + T cell to a fully functional tumor killer cell. Cancer Res 62(22):6438-6441.
40. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174(5):2591-2601.
41. + T-cell differentiation is intrinsic and is not determined by CD4 help. Nat Commun 6:7994.
42. + T cells. Eur J Immunol 39(1):241-253.
43. Aranda F, et al. (2011) Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 71(9):3214-3224.
44. Yuan J, et al. (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105(51):20410-20415.
45. + T cell fates via the graded expression of T-bet transcription factor. Immunity 27(2):281-295.
46. Kaech SM, et al. (2003) Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4(12):1191-1198.
47. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73(12):3591-3603.
48. Marshall JD, et al. (2005) Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol 24(2):63-72.
49. Guiducci C, et al. (2013) RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med 210(13):2903-2919.
50. Guiducci C, et al. (2010) Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 207(13): 2931-2942.